53
Bacteroidetes negatively influence HCT outcomes shown in both animal models and humans [4, 7, 8] .
54
Yet, the relative degree and manner in which various antibiotics and conditioning regimens 55 contribute to microbiota disruption is still not well-described. In previous studies examining the 56 microbiota changes in HCT patients, stool samples were either collected approximately once per week or 57 at a limited number of time points [3-5, 9, 10]. Though these studies helped to form the foundation of 58 our current understanding of microbiota disruption during all-HCT, we posit that a more frequent stool 59 sample collection scheme, combined with dynamic modeling, would be beneficial for providing a higher 60 resolution view of microbiota compositional changes over time, and where individual antibiotic effects 61 can be discerned. Additionally, stool samples from many previous studies were characterized only in terms 62 of relative abundance using 16S sequencing which does not allow quantitative calculations of species loss
63
[11] and therefore, could potentially hamper attempts to quantitatively assess the effects of antibiotics 64 on the microbiota. 
73

Methods
74
Study patients and fecal sample collection
75
We followed 18 adult patients undergoing auto-HCT or allo-HCT at Memorial Sloan Kettering Cancer 
106
Analytic approach
107
We developed and employed a metric of 'compositional volatility' to quantify the rate of overall change 
119
The total abundances of anaerobes were calculated by multiplying the summed relative 
140
We considered a group effect of prophylactic antibiotics (βo) from which each individual 
144
cefepime and linezolid were considered without pooling.
145
We used uninformative priors ( (0, 100 , )) for the growth rate, empirical antibiotics, and the
146
HCT treatment phases, and regularizing priors ( (0, 10 :+ )) for the other parameters. This analysis 147 produced posterior distributions for each parameter after "no U-turn" sampling 10,000 samples from 3 
150
We used the posterior parameter distributions to assess our model. We simulated the predicted 151 changes for each patient's timeline, starting with the first observed anaerobe count from that patient. We 
161
Aggregating all these fold-changes allowed us to calculate the average residual fraction of anaerobes after 162 a 'typical' course of specific antibiotics.
164
Results
165
Description of study population and biospecimens 
194
To quantify day-to-day community shifts, we assessed the compositional volatility of the 195 microbiota between daily intervals, reflecting the overall degree of compositional change over time
196
( Figure 4D, Supplementary Figure 3) . In our patients, microbiota volatility was on average highest 
210
We then predicted the effect of entire courses of piperacillin-tazobactam and meropenem as they 211 occurred among our patients, i.e. including the effects of the period they were administered in (Phase I,
212
Phase II or thereafter) as well as co-administered other antibiotics ( Figure 5B , see methods). Due to 213 differences in the duration of administrations and variation in co-administered antibiotics during these 214 courses, the predicted loss of anaerobes was also variable (e.g. a longer course would yield a larger total 215 loss of anaerobes). Yet, importantly, our model estimated that among our patients, courses with 216 meropenem, and piperacillin-tazobactam each lead to >99% loss of obligate anaerobic bacteria
217
( Figure 5B ).
219
Discussion
220
Under normal circumstances, the human intestinal microbiota is relatively stable over time, and largely
221
consists of obligate anaerobic bacteria [19] . In contrast to this norm, our study shows dramatic day-to- 
231
Here, we show that patients can differ in terms of the rapidity, magnitude and quality of 232 microbiota alterations, which likely reflect differences in baseline microbiota composition, exposure to 
240
We decided to analyze obligate anaerobic bacteria together in a single group (Clostridia, showed a propensity for obligate anaerobe killing, but to a lesser effect. A more robust killing effect on
251
anaerobes by metronidazole may not have been seen because too few patients got this antibiotic (2), and
252
it was often given during phase I and phase II, which may have offset its effect.
253
Our approach also demonstrated a degree of anaerobic impact from cephalosporins (generation 
